Antiplatelet therapy tailoring after primary percutaneous coronary intervention (PCI)

Completed

• Conditions: ST-elevation myocardial infarction (STEMI); Circulatory System; Subsequent myocardial infarction

• Registration Number: ISRCTN64082539
• Lead Sponsor: Clinical Centre of Serbia (Serbia)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-02-18
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 1700

Inclusion Criteria

1. ST-elevation myocardial infection (STEMI) patients undergoing primary PCI in our institution
2. Both genders, aged greater than 18 years
3. Platelet residual aggregation (PRA) assessed 24 hours after the loading with clopidogrel 600 mg
4. Control group: 1000 patients enrolled in the RISK-PCI trial (see http://www.controlled-trials.com/ISRCTN83474650) in our centre from February 1st, 2006 till June 1st, 2008, who did not have platelet function assays

Low responders to clopidogrel will be subjected to ART if there is no exclusion criteria for ART.

Exclusion Criteria

1. Not alive until 24 hours from clopidogrel loading 600 mg
2. Aged greater than 75 years
3. Percutaneous balloon angioplasty (POBA) without stenting
4. Failed pPCI
5. Active bleeding in hospital
6. Coronary dissection with pericardial collection
7. Haemoglobin (Hb) less than 80 g/dL needing transfusion in hospital
8. Simultaneous treatment with oral anticoagulants
9. Candidates for urgent bypass surgery
10. Low basal thrombin receptor activating peptide (TRAP) value (less than 500 AU/minute)
11. Hystory of recent bleeding from ulcer
12. Thrombocyte count less than 100,000/ml
13. Drug non-compliance
14. Withdrawal of consent

Study & Design

• Study Type: Observational
• Study Design: Not specified